Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

Inclusion Criteria:

• 1. Male or female aged 18-60 years.
• 2. Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.
• 3. Chronic HBV infection for ≥ 6 months.
• 4. On NRTI therapy for ≥ 6 months.

Exclusion Criteria:

• 1. Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation.
• 2. Significant liver fibrosis or cirrhosis.
• 3. History or evidence of drug or alcohol abuse.
• 4. History of intolerance to SC or IM injection.
• 5. History of chronic liver disease from any cause other than chronic HBV infection.
• 6. History of hepatic decompensation.
• 7. Contraindications to the use of PEG-IFNα.